Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul;47(7):2327-9.
doi: 10.1128/AAC.47.7.2327-2329.2003.

Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae

Satoshi Ameyama  1 , Yuko Shinmura, Masahiro Takahata
Affiliations

Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae

Satoshi Ameyama et al. Antimicrob Agents Chemother. 2003 Jul.

Abstract

The gyrA and gyrB genes of Chlamydia pneumoniae TW-183 were cloned, and their proteins were purified by use of a fusion system with a maltose-binding protein. The 50% inhibitory concentrations of garenoxacin, sparfloxacin, moxifloxacin, gatifloxacin, and levofloxacin were 10.1, 47.5, 39.6, 64.2, and 156.9 microg/ml, respectively, and the MICs against C. pneumoniae TW-183 were 0.008, 0.016, 0.063, 0.125, and 0.25 microg/ml, respectively.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Enzymatic activities of purified recombinant DNA gyrase of C. pneumoniae TW-183. Lane 1, GyrA-MBP (4 U) and GyrB-MBP (4 U) without ATP; lane 2, GyrA-MBP (4 U) and GyrB-MBP (4 U) without Mg2+; lane 3, GyrA-MBP (8 U) and GyrB-MBP (8 U); lane 4, GyrA-MBP (4 U) and GyrB-MBP (4 U); lane 5, GyrA-MBP (8 U) and GyrB-MBP (3/2 U); lane 6, GyrA-MBP (3/2 U) and GyrB-MBP (8 U); lane 7, GyrA-MBP (2 U) and GyrB-MBP (2 U); lane 8, GyrA-MBP (1 U) and GyrB-MBP (1 U).
FIG. 2.
FIG. 2.
DNA-supercoiling activity of gyrase in the presence of garenoxacin and levofloxacin.
See this image and copyright information in PMC

References

    1. Barlett, J. G., R. F. Breiman, L. A. Mandell, and T. M. File, Jr. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-838. - PubMed
    1. Barlett, J. G., S. F. Dowell, L. A. Mandell, T. M. File, Jr., D. M. Musher, and M. J. Fine. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382. - PMC - PubMed
    1. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425. - PubMed
    1. Dessus-Babus, S., C. M. Bébéar, A. Charron, C. Bébéar, and B. de Barbeyrac. 1998. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob. Agents Chemother. 42:2474-2481. - PMC - PubMed
    1. Donati, M., M. R. Fermepin, A. Olmo, L. D'Apote, and R. Cevenini. 1999. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J. Antimicrob. Chemother. 43:825-827. - PubMed

Associated data

LinkOut - more resources